Management of Osteoarthritis of the Hip Evidence-Based Guideline

Overview of Peer Review and Public Commentary
The reviews and comments related to this clinical practice guideline are reprinted in this document and posted on the AAOS website. All peer reviewers and public commenters are required to disclose their conflict of interests. Names are removed from the forms of reviewers who requested that they remain anonymous; however their COI disclosures still accompany their response.
Peer Review
AAOS contacted 17 organizations with content expertise to review a draft of the clinical practice guideline during the one month peer review period in October 2016.
 Seven individuals provided comments via the electronic structured peer review form. No reviewers asked to remain anonymous.  All seven reviews were on behalf of a society.  The work group considered all comments and made some modifications when they were consistent with the evidence.  The largest modification to the guideline was the removal of the "Limited" recommendation on femoroacetabular impingement syndrome (FAI). For more information, please see the peer review responses on pages 28-29 and the work group's response on page 30.
Public Comment
The new draft was then circulated for a 30-day public comment period ending on February 3 rd , 2017.
 AAOS received two comments, both on behalf of individuals.  If warranted and based on evidence, the guideline draft s modified by the work group members in response to the public comments.
Peer Reviewer Key
Each peer reviewer was assigned a number (see below). All responses in this document are listed by the assigned peer reviewer's number. Peer Reviewers' Disclosure Information
All peer reviewers are required to disclose any possible conflicts that would bias their review via a series of 10 questions (see Table 2 ). For any positive responses to the questions (i.e. "Yes"), the reviewer was asked to provide details on their possible conflict. A. I think there could be better use of MCID criteria. For example in the age-adverse events in THA patients, the use of change in MCID pre to post op should be utilized. B. Also in the age section one of the studies utilized was 20-30 years ago which may not be relevant to current and future use of perioperative pathways. C. The comparison of age studies had random age cutoffs with a difference of 1.49 in the Oxford score. This appears to have a small effect. D. The FAI discussion appears to be an add-on subject. It is relevant in the discussion of hip OA but so is dysplasia (maybe more causality) and this is not discussed. E. With regards to the approach exposure recommendations, the strength of recommendation appears high without randomized studies and longer term follow up.
Workgroup Response Dear Dr. Ernest Sink, Thank you for your expert review of the Clinical Practice Guideline on the Management of Osteoarthritis of the Hip. We will address your comments by guideline section in the order that you listed them.
A. Your point is well-taken. Unfortunately, the varying types of data that was found within the prognostic analysis prohibited us for performing a proper meta-analysis, in which we could have effectively incorporated the MCID statistic to see if age is not only a statistically significant risk factor, but also crosses the clinically important threshold.
B. The 1990 cutoff was selected by the Work Group ahead of time to allow a contemporary window (<26 years) and produce enough data to make an optimal recommendation. This was a judgment call and may have compromised analysis on more rapidly changing practice trends. C. Thank you for pointing this out.
D. Dysplasia is discussed in the "Consensus" section. With the studies that met our inclusion criteria there was noted to be an "absence of reliable" data on this topic to make a weak recommendation. Nevertheless the Work Group determined that PAO may be useful in the treatment of this disorder, and that a consensus statement was warranted. E. All studies used to form recommendations in AAOS clinical practice guidelines undergo a standardized quality evaluation based on modified GRADE criteria. The various criteria assessed to determine the quality of the included articles can be found under each recommendation's "Quality Evaluation" A. Question #1 The guideline objectives are straightforward, appropriate and welldescribed. B. Question #2 The health questions covered by the guideline are clearly described and are relevant to daily practice in the care of patients with osteoarthritis of the hip. C. Question #3 The target audience is clearly outlined and incorporates all of the primary and specialty care groups involved in the care of the target patient population. D. Question #4 asks if the guideline development group includes individuals from all of the relevant professional groups -since this data was removed for this review, I cannot comment on this accurately and must therefore disagree. The reviewer document does not even include the generic names of the specialties. This is problematic as a reviewer and makes it impossible to answer this question. E. Question #5 The guideline authors have done a very good job of linking the available evidence to the recommendations for each clinical question. In the absence of strong data, they have made the source and the rationale for the consensus recommendation explicit. F. Question #6 All of the important clinical outcomes have been taken into consideration in the development of this guideline. G. Question #7 The patient population for whom this guideline is intended is clearly described. H. Question #8 The inclusion and exclusion criteria used to select articles for this guideline are appropriate and provide a sound foundation for developing a high quality, contemporary, evidence based guideline. I. Question #9 The rationale for excluding studies in the guideline is clearly set forth. J. Question #10 The guideline includes the relevant studies for each of the topics. K. Question #11 The process of determining validity of the studies is appropriate and uniformly applied. L. Question #12 The methods are clearly outlined and describe a reproducible process. M. Question #13 The statistical methods are valid. This guideline meets most of the standards of the AGREE II. However, the following areas need to be addressed: -A. List the guideline development group to determine that it includes individuals from all relevant professional groups -B. Describe facilitators and barriers to the guideline's application -C. Provide monitoring and/or auditing criteria.
Workgroup Response
Dear Dr. Richard D. Zorowitz, Thank you for your expert review of the Clinical Practice Guideline on the Management of Osteoarthritis of the Hip. We will address your comments by guideline section in the order that you listed them.
A. We apologize for this oversight. You are correct, it is AAOS procedure to exclude the names of the guideline work group members during peer review and public comment to prevent reviewer bias. This question will be removed for future comment periods. B. This is a great suggestion. A Facilitators and Barriers section has been added to the document. C. Thank you for your suggestion. Monitoring and auditing criteria are addressed by AAOS performance measures.
Respectfully, (1990-present) .
OA Hip Guideline Work Group
A comprehensive list of inclusion criteria are identified in the document. F. 743-745: Excluding controlled trials that did not account for baseline differences among groups or did not randomly assign patients to group, is a strength of this CPG G. 772-780: The criteria established for no recommendation from the synthesis of data are clear and reasonable. H. 782-790: Use of MCID/MID in the evaluation process of the study data enhances the clinical utility of the CPG I. 796-780: Perhaps expanding database searches to include PsychInfo and PEDro may have led to the identification of more research in the rehabilitation/selfmanagement domain. J. 810: The search strategy for PICO 13-15: Does appear in APPENDIX V. Thus, a judgment to the completeness of this search is difficult to make K. APPENDIX IV: The search strategy figure could be enhanced by listing the reasons for exclusion from the guideline and number of articles associated with these exclusions. Though for each PICO question posed this data is provided in the narrative summary for that section. L. 812-863: Assessment of Study Quality: While it appears that the questions used to assess study quality are similar in content to those in included the published CONSORT and STROBE frameworks, the team could include a statement about whether components of these frameworks were used for assessing study quality. Additionally, it is unclear whether members of the review team independently assessed study quality and then met to discuss discrepancies. M. 886-899 Definitions established to make recommendations and statements about clinical relevance are appropriate N. 911-940: Statistical analysis and meta-analytic approaches were appropriate. A strength of the CPG is the inclusion of cost/benefit analyses, when possible. The methodology for determining cost/benefit were appropriate and the group used blinding of the team to cost data to reduce bias. O. PICO14: The question posed is, "In patients with symptomatic hip OA, scheduled for or have undergone total hip replacement, does perioperative/postoperative physical therapy lead to better outcomes compared with patients who do not undergo PT or undergo comparison PTs?" P. In the summary statement, it might be beneficial to discuss the tremendous change in LOS following THR from 1990 to present and the potential impact that change has on the evaluation of peri-operative, but more importantly, post-operative PT.
Reviewer #6, James Slover, MD, MS Please provide a brief explanation of both your positive and negative answers in the preceding section. If applicable, please specify the draft page and line numbers in your comments. Please feel free to also comment on the overall structure and content of the Guideline: 6 James Slover Hip Society
Comments: A. Line 649 -Please give consideration to briefly mentioning shared decision making rather than only informed decision making as surgeons may feel an individual patient's profile makes surgery too high risk. B. Line 1096 -Why are the cannibus / diabetes and adverse events / MRSA etc.
included in this table with no studies? Perhaps some brief description in legend would help. C. Line 1212 -Regarding part (b), there is risk of interpreting this data such that age does not need to be considered when assessing risks of THA. D. Line 1252 -A potential harm is that tobacco cessation will not be as encouraged as much as it should be prior to THA. E. Line 1326 -The term Risk Assessment Tool is confusing to me in this section.
Many of the studies you cite, use WOMAC, SF-36 and EQ-5D instruments, which measure function and quality of life, but not necessarily risk. They imply that patients with lower function or quality of life pre operatively may expect lower function or quality of life after surgery, but they don't asses risks of complications. Also, some studies assess impact comorbidities such as diabetes on complications, but the guideline was not able to have a specific recommendation on those individual comorbidities. F. Line 1350 -I would adding a statement/phrase that states modifiable risk factors that have been shown to positively impact outcomes, as opposed to risk factors that are modifiable, but changing them does not improve outcomes. G. Line 1406 -Why no mention of potential future research on NSAIDs, such as longterm effects or other agents commonly used? H. Line 1510 -Infection is mentioned as a potential harm with these injections, but there is some recent evidence that these infections may pose longer term risk if THA is later done as well. This is causing many to move away from these injections, especially in those with severe arthritis and I am concerned this guideline goes against that. Is there consideration to mention that here? I. Line 2014: -Might consider commenting on definitive impact on blood transfusions, which have many known negatives and high cost, as well.
J. Line 2083 -Although there may not be studies that met the criteria of the review, there are many studies on benefits of neuroaxial anesthesia and the wording of the recommendation may decrease use of this technique. K. Line 2160 -Why no further research needed?
Workgroup Response Dear Dr. James Slover, Thank you for your expert review of the Clinical Practice Guideline on the Management of Osteoarthritis of the Hip. We will address your comments by guideline section in the order that you listed them.
A. This sentence has been revised to read, "Once the patient and/or their decision surrogate have been informed of available therapies and have discussed these options with the patient's physician, an informed and shared decision can be made." B. This is a very good suggestion. The explanation is that no evidence was discovered to answer these a priori PICO questions. This explanation will be added to the legend of the chart. C. The work group acknowledges your concerns; however, the interpretation that age is a possible risk factor is clearly expressed via the recommendation language. D. Lines 1248-1250 note the priority of engaging patients in the health benefits of smoking cessation.
However, the work group strongly believes that the potential harm of not having access to THR because of the patient's unwillingness to stop smoking must to be mentioned in the possible harms section. E. Your comment is well-taken. The reviewer brings up an important point regarding language and illustrates the challenge of searching for a variety of studies on this topic using language that has changed over the years. With the modern concerns in hip and knee arthroplasty regarding risk mitigation, the term "risk assessment tool" has different meaning than it may have in years past. That being said, the original PICO question, resulting literature search, and framework for this recommendation was based off of the terms "risk assessment tool" and the articles used for the recommendation were defined in the journals as "risk-assessment tools". The work group has added the following statement to the future research section, "Future studies should attempt to better delineate between clinical outcome tools and risk assessment tools which incorporate comorbidities such as diabetes, tobacco use, etc." F. Thank you for your suggestion. G. The work group has added the following statement to the future research section, "Future studies performed assessing the efficacy and potential complications of long-term use of NSAIDs for the treatment of symptomatic hip osteoarthritis may be of benefit." H. The work group has refined the harms statement to read, "Risks of corticosteroid IA injection include bleeding, potential injury to adjacent structures, transient pain, allergic reaction, and infection before and after total hip arthroplasty, post-injection pain flare and hyperglycemia." I. The work group has refined the harms statement to read, "Randomized, prospective trials comparing IV TXA, topical TXA, and oral TXA are warranted to specifically assess dosing, technique and timing of administration, uniform measures of perioperative blood loss, cost, including impact on blood transfusion, and contraindications." J. With the limited comparative evidence the statement cannot definitively ascribe specific harms to either modality, particularly when deciding which modality to use. K. The work group agrees that a future research section is warranted. The following statement has been added to the future research section: "Future randomized clinical trials and longitudinal cohort studies are warranted to better investigate surgical and nonsurgical treatment techniques for FAI treatment, as well as to assess the natural history of symptomatic and asymptomatic FAI patients with or without treatment." A. Thank you for your comment. As a reminder, these are not consensus statements, rather they are evidence-based statements. The language template presented in the Methodology section is a guide for the work group members, not prescriptive. The work group carefully assembles the language for each recommendation based on the quality of the evidence, the directionality of the evidence findings, and thinking forward to usability of the guideline at the point of care. B. After much discussion between the guideline work group chairs and the leaders of the AAOS EvidenceBased Quality and Value Committee regarding your concerns, we have found your comments to be valid and have made the decision to remove the FAI recommendation from this guideline, with the understanding that the AAOS will address this topic in a future hip preservation guideline. C. See B. D. The work group agrees with the reviewer that the first sentence is confusing. Our rationale was written with knowledge that we were assessing PAO, other open surgery (femoral osteotomy, surgical hip dislocation), and/or hip arthroscopy to treat FAI, but our rationale only discusses arthroscopy vs surgical hip dislocation. This sentence has been rewritten as follows: "Only four studies, 3 low quality… analysis of whether patients with symptomatic FAI reported better outcomes with open or arthroscopic hip surgery. Due to the heterogeneous study cohorts, varying study questions, differing……." Four studies, 3 low quality (Domb et al; Nepple et al; Zingg et al) and 1 high quality (Krych et al), met the strict criteria for inclusion in the analysis of whether patients with symptomatic FAI reported better outcomes with open or arthroscopic hip surgery." E. You are correct that the evidence is in support of TXA; however, the strength of the recommendation is based on the quality of the evidence, which is also dependent on if each study is evaluating similar types of the same treatment. The literature discovered for the TXA recommendation was high and moderate quality but highly variable which limited the strength of the recommendation to "Moderate". F. Your comment is noted. Since there were other risk factors discovered via the literature search (i.e.
anxiety and psychosis), the recommendation language must remain as-is. The rationale does clarify the quantity of the articles identifying depression as a risk factor. G. The scope of this CPG is to assess the management of hip OA in relationship to known treatment alternatives. Other than analysis of results using various surgical approaches to the hip in THR, the more technical aspects of THR were not thought to be appropriate for inclusion, but may be well suited for the accompanying appropriate use criteria (AUC).
Respectfully,
Public Commenters' Disclosure Information
All public commenters are required to disclose any possible conflicts that would bias their review via a series of 10 questions (see Table 2 ). For any positive responses to the questions (i.e. "Yes"), the reviewer was asked to provide details on their possible conflict. Please provide a brief explanation of both your positive and negative answers in the preceding section. If applicable, please specify the draft page and line numbers in your comments. Please feel free to also comment on the overall structure and content of the Guideline:
The "Age as a Risk Factor" recommendation, a), is not in agreement with a recent JAAOS article about total joint replacement in the elderly (October 2016). Specifically, outcomes were thought not be inferior in the elderly in the JAAOS article. However, the CPG is accurate in that the individual studies cited in the article suggested that the outcomes of THA were lower in those >80 yo but not for TKA. The problem is that the JAAOS article lumped TKA and THA together, so that the conclusions were that the two procedures generally produced comparable outcomes in patients older than 80 yo. This is an issue for the JAAOS article, not the CPG, but may come across as an inconsistency when reviewed together.
Workgroup Response
Dear Dr. Christopher Bono, Thank you for your expert review of the Clinical Practice Guideline on the Management of Osteoarthritis of the Hip. Your insight on the discrepancies between our guideline's findings and the findings suggested in the JAAOS article is very insightful and we will be prepared to address differences should the issue present itself.
Respectfully, 2016 OA Hip Guideline Work Group
